Free tool
FAERS Monitor: Remodulin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208276 or its brand name (Remodulin, Treprostinil). Reports on generic versions are filed under their own applications.
Reports
64,707
Serious
41,543
64% of reports
Hospitalization
30,991
Death reported
9,004
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea9,869
- headache7,151
- diarrhoea6,878
- nausea6,178
- infusion site pain5,787
- death5,212
- fatigue4,057
- dizziness3,833
- vomiting3,379
- infusion site erythema3,348
- pain in extremity2,962
- hypotension2,833
- pulmonary arterial hypertension2,822
- malaise2,789
- pneumonia2,674
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 31 |
| 2005 | 58 |
| 2006 | 86 |
| 2007 | 39 |
| 2008 | 31 |
| 2009 | 64 |
| 2010 | 889 |
| 2011 | 1,616 |
| 2012 | 642 |
| 2013 | 998 |
| 2014 | 4,571 |
| 2015 | 5,443 |
| 2016 | 4,819 |
| 2017 | 4,835 |
| 2018 | 5,286 |
| 2019 | 4,950 |
| 2020 | 4,256 |
| 2021 | 4,001 |
| 2022 | 4,300 |
| 2023 | 5,013 |
| 2024 | 4,579 |
| 2025 | 4,856 |
| 2026 | 3,344 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,989,452 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site painSignal | 5,787 | 263.9 | 255.1 | 836,104 |
| infusion site erythemaSignal | 3,348 | 213.3 | 204.4 | 426,866 |
| pulmonary arterial hypertensionSignal | 2,822 | 78.4 | 75.3 | 173,633 |
| dyspnoeaSignal | 9,869 | 5.7 | 5.6 | 39,093 |
| hypotensionSignal | 2,833 | 4.6 | 4.5 | 8,054 |
| headacheSignal | 7,151 | 3.7 | 3.7 | 14,615 |
| diarrhoeaSignal | 6,878 | 3.5 | 3.4 | 12,469 |
| pain in extremitySignal | 2,962 | 3.3 | 3.2 | 4,740 |
| pneumoniaSignal | 2,674 | 2.7 | 2.6 | 2,878 |
| nauseaSignal | 6,178 | 2.5 | 2.5 | 5,996 |
| dizzinessSignal | 3,833 | 2.5 | 2.4 | 3,536 |
| vomitingSignal | 3,379 | 2.3 | 2.3 | 2,648 |
| malaiseSignal | 2,789 | 2.1 | 2.0 | 1,573 |
| death | 5,212 | 2.0 | 1.9 | 2,588 |
| fatigue | 4,057 | 1.7 | 1.6 | 1,200 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.